Get the Stockscreener App
4.84
2.81%
-0.14
After Hours:
4.85
0.010
+0.21%
Verve Therapeutics Inc stock is traded at $4.84, with a volume of 814.92K.
It is down -2.81% in the last 24 hours and down -27.76% over the past month.
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$4.98
Open:
$4.89
24h Volume:
814.92K
Relative Volume:
0.58
Market Cap:
$407.89M
Revenue:
$20.65M
Net Income/Loss:
$-192.65M
P/E Ratio:
-1.5268
EPS:
-3.17
Net Cash Flow:
$-134.39M
1W Performance:
-3.59%
1M Performance:
-27.76%
6M Performance:
-63.55%
1Y Performance:
-63.50%
1-Day Range:
$4.79
$5.09
1-Week Range:
$4.76
$5.11
52-Week Range:
$4.305
$20.12
Verve Therapeutics Inc Stock (VERV) Company Profile
Name
Verve Therapeutics Inc
Sector
Industry
Phone
(978) 501-3026
Address
201 BROOKLINE AVENUE, BOSTON
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-23 | Initiated | Canaccord Genuity | Buy |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-15-22 | Initiated | Goldman | Sell |
| Oct-06-22 | Initiated | Credit Suisse | Neutral |
| Aug-25-22 | Upgrade | Stifel | Hold → Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Feb-18-22 | Initiated | RBC Capital Mkts | Outperform |
| Sep-24-21 | Initiated | Stifel | Hold |
| Jul-12-21 | Initiated | Guggenheim | Buy |
| Jul-12-21 | Initiated | JP Morgan | Neutral |
| Jul-12-21 | Initiated | Jefferies | Buy |
| Jul-12-21 | Initiated | William Blair | Outperform |
View All
Verve Therapeutics Inc Stock (VERV) Latest News
H.C. Wainwright initates Verve Therapeutics Inc (VERV) rating to a Buy - Knox Daily
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: - GlobeNewswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve - The Bakersfield Californian
Analyzing Ratios: Verve Therapeutics Inc (VERV)’s Financial Story Unveiled - The Dwinnex
Verve Therapeutics Inc (VERV)’s stock price range in the last year - US Post News
7 Best NASDAQ Stocks Under $5 - Insider Monkey
ROSEN, A LEADING NATIONAL FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel - The Bakersfield Californian
ROSEN, A LEADING NATIONAL FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - GlobeNewswire Inc.
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) should contact Levi & Korsinsky about pending Class ActionVERV - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - Morningstar
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - PR Newswire
VERV Stock Sees Decline of Approximately -13.43% in Last Five Days - Knox Daily
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - Lelezard
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Verve Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - GlobeNewswire Inc.
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - Morningstar
Bragar Eagel & Squire, P.C. Reminds Investors That Class - GlobeNewswire
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - Daily Guardian Canada
SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - GlobeNewswire
Verve Therapeutics Inc (VERV) is looking forward to a strong quarter - SETE News
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc.VERV - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm - PR Newswire
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - Stockhouse Publishing
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Was there any good news for Verve Therapeutics Inc (VERV) stock in the last session? - US Post News
Levi & Korsinsky Notifies Shareholders of Verve Therapeutics, Inc.(VERV) of a Class Action Lawsuit and an Upcoming Deadline - PR Newswire
VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit - Stockhouse Publishing
Investing in Verve Therapeutics Inc (VERV) Is Getting More Attractive - Knox Daily
Ratios in Focus: Analyzing Verve Therapeutics Inc (VERV)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024VERV - PR Newswire
VERVE THERAPEUTICS, INC. (NASDAQ: VERV) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Verve Therapeutics, Inc. Investors of Upcoming Deadline - ForexTV.com
2024-09-22 | SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics | NDAQ:VERV | Press Release - Stockhouse Publishing
DekaBank Deutsche Girozentrale Sells 2,690 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verve - GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm – VERV - GlobeNewswire Inc.
Jim Cramer on Vertiv Holdings (VRT): ‘I Think It’s A Winner’ - Yahoo Finance
VERV SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
VERV’s Stochastic Averages Dip: Analyzing Verve Therapeutics Inc’s Stock Performance - The InvestChronicle
Jim Cramer on Verve Therapeutics Inc. (VERV): ‘I Think It’s A Winner’ - Insider Monkey
Insider Buying: Ashe Andrew D., Verve Therapeutics Inc [VERV] insider invested 76,000 shares - Knox Daily
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics - GlobeNewswire
VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Shareholders with Losses Have Opportunity to Lead Class Action Lawsuit! - AccessWire
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of October 28, 2024 in Verve Therapeutics LawsuitVERV - PR Newswire
Verve Therapeutics, Inc. (NASDAQ:VERV) Position Trimmed by Federated Hermes Inc. - MarketBeat
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – VERV - MSN
Views of Wall Street’s Leading Experts on Verve Therapeutics Inc - SETE News
Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – VERV - ForexTV.com
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Acquired by Daiwa Securities Group Inc. - Defense World
Shareholders that lost money on Verve Therapeutics, Inc.(VERV) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - Invezz
VERV CLASS ACTION: Verve Therapeutics, Inc. Stockholders Should Contact Robbins LLP for Information About the Securities Class Action Lawsuit - ForexTV.com
Verve Therapeutics Inc Stock (VERV) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):